Injection, nivolumab
Products billed under this code include Opdivo.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Opdivo.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Opdivo | E.R. Squibb & Sons, L.L.C. | 00003-3734-13 | 240 | $8,205.84 |
| Opdivo | E.R. Squibb & Sons, L.L.C. | 00003-3756-14 | 120 | $4,102.92 |
| Opdivo | E.R. Squibb & Sons, L.L.C. | 00003-3772-11 | 40 | $1,367.64 |
| Opdivo | E.R. Squibb & Sons, L.L.C. | 00003-3774-12 | 100 | $3,419.10 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $34.191 | −$0.031 | 1 MG | Injection, nivolumab | v1, posted September 17, 2026 |
| 3Q26 | $34.222 | +$0.598 | 1 MG | Injection, nivolumab | v1, posted September 15, 2026 |
| 2Q26 | $33.624 | +$0.051 | 1 MG | Injection, nivolumab | v1, posted September 15, 2026 |
| 1Q26 | $33.573 | +$0.609 | 1 MG | Injection, nivolumab | v1, posted September 15, 2026 |
| 4Q25 | $32.964 | −$0.038 | 1 MG | Injection, nivolumab | v1, posted September 8, 2026 |
| 3Q25 | $33.002 | +$0.65 | 1 MG | Injection, nivolumab | v1, posted March 10, 2026 |
| 2Q25 | $32.352 | +$0.056 | 1 MG | Injection, nivolumab | v1, posted March 10, 2026 |
| 1Q25 | $32.296 | +$0.546 | 1 MG | Injection, nivolumab | v1, posted December 19, 2025 |
| 4Q24 | $31.75 | +$0.154 | 1 MG | Injection, nivolumab | v1, posted June 11, 2025 |
| 3Q24 | $31.596 | +$0.502 | 1 MG | Injection, nivolumab | v1, posted June 11, 2025 |
| 2Q24 | $31.094 | +$0.005 | 1 MG | Injection, nivolumab | v1, posted March 11, 2025 |
| 1Q24 | $31.089 | +$0.663 | 1 MG | Injection, nivolumab | v1, posted December 19, 2024 |
| 4Q23 | $30.426 | −$0.031 | 1 MG | Injection, nivolumab | v1, posted October 10, 2024 |
| 3Q23 | $30.457 | +$0.546 | 1 MG | Injection, nivolumab | v1, posted June 5, 2024 |
| 2Q23 | $29.911 | −$0.09 | 1 MG | Injection, nivolumab | v1, posted February 23, 2024 |
| 1Q23 | $30.001 | +$0.454 | 1 MG | Injection, nivolumab | v1, posted December 6, 2023 |
| 4Q22 | $29.547 | −$0.138 | 1 MG | Injection, nivolumab | v1, posted June 22, 2023 |
| 3Q22 | $29.685 | +$0.447 | 1 MG | Injection, nivolumab | v1, posted June 9, 2023 |
| 2Q22 | $29.238 | −$0.007 | 1 MG | Injection, nivolumab | v1, posted December 14, 2022 |
| 1Q22 | $29.245 | +$0.382 | 1 MG | Injection, nivolumab | v1, posted June 8, 2022 |
| 4Q21 | $28.863 | −$0.032 | 1 MG | Injection, nivolumab | v1, posted June 2, 2022 |
| 3Q21 | $28.895 | +$0.408 | 1 MG | Injection, nivolumab | v1, posted June 2, 2022 |
| 2Q21 | $28.487 | −$0.054 | 1 MG | Injection, nivolumab | v1, posted March 1, 2022 |
| 1Q21 | $28.541 | – | 1 MG | Injection, nivolumab | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.